HC Surgical Specialists Ltd
SGX:1B1
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.24
0.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SGD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
HC Surgical Specialists Ltd
HC Surgical Specialists Ltd
Cost of Revenue
HC Surgical Specialists Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
HC Surgical Specialists Ltd
SGX:1B1
|
Cost of Revenue
-S$2.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Cordlife Group Ltd
SGX:P8A
|
Cost of Revenue
-S$17.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-2%
|
|
|
Q & M Dental Group (Singapore) Ltd
SGX:QC7
|
Cost of Revenue
-S$21.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Healthway Medical Corporation Ltd
SGX:5NG
|
Cost of Revenue
-S$26.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
T
|
Talkmed Group Ltd
SGX:5G3
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EUDA Health Holdings Ltd
NASDAQ:EUDA
|
Cost of Revenue
-$2.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
HC Surgical Specialists Ltd
Glance View
HC Surgical Specialists Ltd. is an investment holding company, which engages in healthcare segment. The firm is engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services. The firm focuses on colorectal procedures across a network of clinics located throughout Singapore. The company also provides medical care, consultancy, treatment and surgery in the field of colorectal endoscopy, vein and vascular. The firm treats a range of conditions, including hemorrhoids, anal abscesses, anal fissures, gallstones and inflammation of the gallbladder, hernias, colorectal cancer, stomach cancer, colonic diverticular disease, and cysts and lipomas. The firm's clinics are located in central Singapore, as well as, in residential areas, including the heartlands. The firm operates a wide network of clinics located throughout Singapore, in both residential areas and central areas, which are accessible to the public for consultation.
See Also
What is HC Surgical Specialists Ltd's Cost of Revenue?
Cost of Revenue
-2.8m
SGD
Based on the financial report for May 31, 2024, HC Surgical Specialists Ltd's Cost of Revenue amounts to -2.8m SGD.
What is HC Surgical Specialists Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-7%
Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for HC Surgical Specialists Ltd have been 3% over the past three years , -7% over the past five years .
You don't have any saved screeners yet
